EX-12.1 3 ex12_103312012.htm PROGENICS EXHIBIT 12.1 03/31/2012 ex12_103312012.htm


Exhibit 12.1
 
Progenics Pharmaceuticals, Inc.
Ratio of Earnings (Loss) to Combined Fixed Charges and Preferred Stock Dividends
(in thousands)
 
   
Three Months
Ended
March 31,
    
Years Ended December 31,
  
   
2012
    
2011
    
2010
    
2009
    
2008
    
2007
  
Determination of earnings (loss):
                                    
Income (loss) from operations
   $ (13,086 )   $ 10,381     $ (69,820 )   $ (30,612 )   $ (44,672 )   $ (43,688 )
Add:
                                                
Fixed charges
     17       695       709       555       594       483  
                                                 
Earnings (loss), as adjusted
   $ (13,069 )   $ 11,076     $ (69,111 )   $ (30,057 )   $ (44,078 )   $ (43,205 )
                                                 
Fixed charges:
                                                
                                                 
Estimate of interest within rental expense
     17       695       709       555       594       483  
                                                 
Fixed charges
   $ 17     $ 695     $ 709     $ 555     $ 594     $ 483  
                                                 
Preferred stock dividends
   $ -     $ -     $ -     $ -     $ -     $ -  
                                                 
                                                 
Ratio of earnings (loss) to fixed charges and preferred stock dividends
     *       16       *       *       *       *  
Coverage deficiency amount for total fixed charges and preferred stock dividends (1)
   $ 13,086     $ -     $ 69,820     $ 30,612     $ 44,672     $ 43,688  
________________
(1)
For the years ended 2007 through 2010 and for the three months ended March 31, 2012, the Company’s coverage ratio is less than one-to-one and it must generate additional earnings of these specified amounts to achieve a coverage ratio of 1:1.